AlphAIAlphAI — Financial news for AI agents
investing.comNOV 32 min read$AMGN

Why is Amgen stock sliding today?

Amgen (AMGN) stock fell 1.6% in after-hours trading despite beating earnings estimates. Revenue rose 8% to $10.4B, but Prolia and XGEVA sales dropped 45% and 47% respectively due to biosimilar competition. Guidance was in line with expectations, and R&D expenses increased 11%. The broader market was mixed, with midterm elections adding macro uncertainty.

Original reporting
investing.com
Published Nov 3, 2026, 9:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AMGN
Bearish
medium confidence
Mentioned
$AMGN
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AMGNBearishMed
01

Why it matters

The mixed earnings narrative triggered a modest after‑hours sell‑off, highlighting investor sensitivity to product erosion despite overall top‑line growth.

02

Market read

Amgen's earnings release provides fresh data on revenue growth and product challenges, influencing biotech valuations.

03

What to watch

Potential upside from upcoming pipeline launches and possible cost‑cutting measures not yet disclosed.

Relevance 8/10Novelty 8/10Timing: after‑hours today

Background

Amgen reported Q2 2026 results with EPS $6.45 and revenue $10.4 B, beating estimates but showing sharp drops in Prolia and XGEVA sales due to biosimilar competition.

Company-level read

Ticker impact

$AMGNBearishMedium confidence
Context

Amgen stock slipped 1.6% in after‑hours trading despite an earnings beat, as biosimilar competition eroded legacy product sales.

Expected impact

likely further downside as the market prices in margin pressure from biosimilar competition.

Evidence & confidence

The earnings beat was offset by weak product trends and flat guidance, prompting a sell‑off.

Market effects

Sector

Biotech sector may see heightened scrutiny on legacy drug pipelines and biosimilar exposure.

Regional

U.S. large‑cap biotech stocks could face modest pressure in the near term.

Global

Limited to investors with exposure to Amgen and comparable biotech firms.

Counterpoint

What could challenge this read

The earnings beat and raised full‑year guidance could support a rebound if the market overreacts to short‑term product declines.

Key entities

  • company
    Amgen Inc.

    U.S. biotech giant reporting Q2 earnings.

Read at source← All news

StoryAmgen posts Q3 2026 earnings, lifts full‑year revenue and EPS outlook

Also covered by

5 outlets

Related articles

NOV 4
$AMGNMedAI 8/10

What Amgen (AMGN) Said on Its Q3 Earnings Call

Amgen reported Q3 sales growth in rare diseases and oncology, with BLINCYTO up 27% and TEPEZZA down 6%. Positive phase III results were announced for small cell lung cancer, eosinophilic esophagitis, and Sjögren's disease. MariTide obesity drug trials are advancing. Amgen raised 2026 revenue guidance to $38.9B-$39.7B and EPS to $22.90-$23.70, with a 6% dividend increase.

finance.yahoo.com7 min
NOV 3
$AMGNHighAI 9/10

AMGN Q3 FY2026 earnings call

Amgen reported Q3 2026 revenue of $10.4B, up 8% YoY, with 17 products growing double-digit. Non-GAAP operating margin was 47%, and free cash flow reached $3.7B. The company raised full-year 2026 guidance, expecting revenue of $38.9B-$39.7B and EPS of $22.90-$23.70. Key growth drivers include Repatha, EVENITY, TEZSPIRE, and UPLIZNA, with notable increases in rare disease and oncology portfolios.

finance.biggo.com2 min